

Supplementary Table S1. Overview of Outcome Measures, Sample Sizes, and Post-hoc Power

Considerations					
Category	Specific Metric & Comparison	Sample Size (per group)	Effect Size (Cohen's d)	Statistical Power	Notes and Rationale
Primary Outcome	Serum Creatinine (Scr) at 24 h (I/R+MSCs vs I/R+sFgl2-MSCs)	n = 6	2.05	~98%	Primary endpoint. Power is sufficient.
Key Secondary Outcomes	Serum Urea Nitrogen (BUN) at 24 h (I/R+MSCs vs I/R+sFgl2-MSCs)	n = 6	1.97	~95%	Supports the primary conclusion.
	Plasma cf-DNA Level at 24 h (I/R+MSCs vs I/R+sFgl2-MSCs)	n = 6	1.95	~94%	Reflects NETosis and tissue injury.
	Peripheral Blood Neutrophil Proportion at 24 h (I/R+MSCs vs I/R+sFgl2-MSCs)	n = 6	2.08	~98%	Reflects systemic inflammation.
Exploratory <i>In Vitro</i> Experiments	e.g., Neutrophil N2 proportion, Cytokine levels, etc.	Typically n = 3	Not calculated	Not calculated	Preliminary mechanistic investigations. Sample size was set based on pilot observations and common practice for exploratory studies, aiming to provide initial proof-of-concept. Conclusions require future validation with larger samples.